Rapid Development of Hepatocellular Carcinoma after Eradication of Hepatitis C Virus with Directly Acting Antiviral Treatment — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Rapid Development of Hepatocellular Carcinoma after Eradication of Hepatitis C Virus with Directly Acting Antiviral Treatment
Section of Gastroenterology, Department of Medicine, The Aga Khan University, Karachi, Pakistan
,
Section of Gastroenterology, Department of Medicine, The Aga Khan University, Karachi, Pakistan
1 Section of Gastroenterology, Department of Medicine, The Aga Khan University, Karachi, Pakistan
2 Section of Gastroenterology, Department of Medicine, The Aga Khan University, Karachi, Pakistan
Hepatitis C is a major risk factor for the development of hepatocellular carcinoma (HCC), arising typically on a background of liver cirrhosis. Treatment of hepatitis C has been revolutionized by the addition of oral direct-acting antivirals (DAAs) with sustained virological response (SVR) rates above 90%. There is a recent concern under debate about the increased risk of early HCC recurrence in patients with chronic hepatitis C who were treated with direct-acting antivirals. Nonetheless, these reports mostly focused on patients who were cirrhotic and were already treated for HCC. We report 4 cases of treatment naive, chronic hepatitis C patients who were treated with DAAs and rapidly developed infiltrative HCC despite achieving SVR. Moreover, in our scenario, one of the patients appeared clinically non-cirrhotic until he developed HCC.
Singal, A.G., Volk, M.L., Jensen, D., Di Bisceglie, A.M. and Schoenfeld, P.S. (2010) A Sustained Viral Response Is Associated with Reduced Liver-Related Morbidity and Mortality in Patients with Hepatitis C Virus. Clinical Gastroenterology and Hepatology, 8, 280-288.
Vezali, E., Aghemo, A. and Colombo, M. (2010) A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis. Clinical Therapeutics, 32, 2117-2138. https://doi.org/10.1016/S0149-2918(11)00022-1
Livingston, S.E., Townshend-Bulson, L.J., Bruden, D.J., Homan, C.E., Gove, J.E., Plotnik, J.N., et al. (2016) Results of Interferon-Based Treatments in Alaska Native and American Indian Population with Chronic Hepatitis C. International Journal of Circumpolar Health, 75, Article ID: 30696. https://doi.org/10.3402/ijch.v75.30696
Mashitani, T., Yoshiji, H., Yamazaki, M., Ikenaka, Y., Noguchi, R., Ishikawa, M., et al. (2009) Development of Hepatocellular Carcinoma in a Patient 13 Years after Sustained Virological Response to Interferon against Chronic Hepatitis C: A Case Report. Cases Journal, 2, 18. https://doi.org/10.1186/1757-1626-2-18
Igarashi, G., Endo, T., Sawada, N., Mikami, K., Sato, K., Kudo, D., et al. (2015) Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients 20 Years after Achieving a Sustained Virological Response with Interferon Therapy: A Report of Two Cases. Journal of General and Family Medicine, 16, 199-203. https://doi.org/10.14442/jgfm.16.3_199
Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M. and Falck-Ytter, Y. (2013) Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Annals of Internal Medicine, 158, 329-337.
El-Serag, H.B., Kanwal, F., Richardson, P. and Kramer, J. (2016) Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with Hepatitis C Virus Infection. Hepatology, 64, 130-137.
Forestier, N., Reesink, H.W., Weegink, C.J., McNair, L., Kieffer, T.L., Chu, H.M., et al. (2007) Antiviral Activity of Telaprevir (VX-950) and Peginterferon Alfa-2a in Patients with Hepatitis C. Hepatology, 46, 640-648. https://doi.org/10.1002/hep.21774
Fried, M.W., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I., et al. (2013) Once-Daily Simeprevir (TMC435) with Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Hepatitis C: The Randomized PILLAR Study. Hepatology, 58, 1918-1929. https://doi.org/10.1002/hep.26641
American Association for the Study of Liver Diseases and Infectious Diseases Society of America (2016) HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
European Association for the Study of the Liver (2017) EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology, 66, 153-194.
World Health Organization (2016) Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection.
Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. (2016) Unexpected High Rate of Early Tumor Recurrence in Patients with HCV-Related HCC Undergoing Interferon-Free Therapy. Journal of Hepatology, 65, 719-726. https://doi.org/10.1016/j.jhep.2016.04.008
Nault, J.-C. and Colombo, M. (2016) Hepatocellular Carcinoma Anddirect Acting Antiviral Treatments: Controversy after the Revolution. Journal of Hepatology, 65, 663-665. https://doi.org/10.1016/j.jhep.2016.07.004
Llovet, J.M. and Villanueva, A. (2016) Liver Cancer: Effect of HCV Clearance with Direct-Acting Antiviral Agents on HCC. Nature Reviews Gastroenterology & Hepatology, 13, 561-562. https://doi.org/10.1038/nrgastro.2016.140
Serti, E., Chepa-Lotrea, X., Kim, Y.J., Keane, M., Fryzek, N., Liang, T.J., et al. (2015) Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology, 149, 190-200.e2.
Bruix, J., Gores, G.J. and Mazzaferro, V. (2014) Hepatocellular Carcinoma: Clinical Frontiers and Perspectives. Gut, 63, 844-855. https://doi.org/10.1136/gutjnl-2013-306627
Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., et al. (2016) Unexpected High Incidence of Hepatocellular Carcinoma in Cirrhotic Patients with Sustained Virologic Response Following Interferon-Free Direct-Acting Antiviral Treatment. Journal of Hepatology, 65, 856-858. https://doi.org/10.1016/j.jhep.2016.06.009
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. (2016) Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Journal of Hepatology, 65, 727-733. https://doi.org/10.1016/j.jhep.2016.06.015
Cardoso, H., Vale, A.M., Rodrigues, S., Gonçalves, R., Albuquerque, A., Pereira, P., et al. (2016) High Incidence of Hepatocellular Carcinoma Following Successful Interferon-Free Antiviral Therapy for Hepatitis C Associated Cirrhosis. Journal of Hepatology, 65, 1070-1071. https://doi.org/10.1016/j.jhep.2016.07.027
Pol, S. (2016) Lack of Evidence of an Effect of Direct-Acting Antivirals on the Recurrence of Hepatocellular Carcinoma: Data from Three ANRS Cohorts. Journal of Hepatology, 65, 734-740. https://doi.org/10.1016/j.jhep.2016.05.045
Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al. (2016) Outcomes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 65, 741-747. https://doi.org/10.1016/j.jhep.2016.06.019
Kobayashi, M., Suzuki, F., Fujiyama, S., Kawamura, Y., Sezaki, H., Hosaka, T., et al. (2017) Sustained Virologic Response by Direct Antiviral Agents Reduces the Incidence of Hepatocellular Carcinoma in Patients with HCV Infection. Journal of Medical Virology, 89, 476-483. https://doi.org/10.1002/jmv.24663
Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., et al. (2017) Hepatocellular Carcinoma Recurrence in Patients with Curative Resection or Ablation: Impact of HCV Eradication Does Not Depend on the Use of Interferon. Alimentary Pharmacology & Therapeutics, 45, 160-168. https://doi.org/10.1111/apt.13821
Romano, A., Capra, F., Piovesan, S., Chemello, L., Cavalletto, L., Anastassopoulos, G., et al. (2016) Incidence and Pattern of “De Novo” Hepatocellular Carcinoma in HCV Patients Treated with Oral DAAs. 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting, Boston, 11-15 November 2016.
Bertolini, E., Bassi, F. and Fornaciari, G. (2013) Development of Hepatocellular Carcinoma in a Non-Cirrhotic, Long-Term Responder to Antiviral Therapy, Chronic Hepatitis C Patient: What Kind of Surveillance? Annals of Gastroenterology, 26, 80-83.